Compositions and methods for treating cancer
Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.
1. A method of treating a solid metastatic tumor in a subject in need thereof, the method comprising:
(a) administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1, said therapeutically effective amount induces mobilization and dissemination of immature dendritic cells, T effector cells and memory cells into the tumor; and
(b) administering to the subject a therapeutically effective amount of a PD1 antagonist, thereby treating the solid metastatic tumor in the subject.
2. The method of claim 1 , wherein said solid metastatic tumor is pancreatic cancer.
3. The method of claim 1 , wherein said PD1 antagonist is an anti-PD1 antibody.
4. The method of claim 1 , wherein said solid metastatic tumor is pancreatic cancer, wherein said PD1 antagonist is an anti-PD1 antibody and wherein said peptide is as set forth in SEQ ID NO: 1.